EDISON EQUITY RESEARCH: TRIMEL PHARMACEUTICALS - ENDO TO PARTNER NATESTO

Trimel is partnering its Natesto intranasal gel testosterone replacement therapy (TRT) product in the US and Mexico with Endo Pharmaceuticals, receiving US$25m upfront and a tiered supply price for manufacturing. Endo’s marketed portfolio of TRT products makes it an ideal partner, and Trimel expects to be ready for commercial manufacturing in Q115.

Trimel is a Canadian specialty pharmaceutical company. Natesto and Tefina deliver testosterone through a bio-adhesive nasal gel drug delivery technology platform, for male hypogonadism and female orgasmic disorder (FOD), respectively. Estrace is being marketed for HRT in Canada.

To view our full report, please click here:
http://www.edisoninvestmentresearch.com/research/report/trimel-pharmaceuticals6

Click here to view all of Edison Investment Research’s published reports 


Grafico Azioni Trilogy International Pa... (TSX:TRL)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Trilogy International Pa...
Grafico Azioni Trilogy International Pa... (TSX:TRL)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Trilogy International Pa...